Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $51.9 Billion by 2030
The global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$31.1 Billion in the year 2023, is expected to reach US$51.9 Billion by 2030, growing at a CAGR of 7.6% over the period 2023-2030. Stimulant Drugs, one of the segments analyzed in the report, is expected to record 7.1% CAGR and reach US$43 Billion by the end of the analysis period. Growth in the Non-Stimulant Drugs segment is estimated at 10.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $9.2 Billion, While China is Forecast to Grow at 7.1% CAGR
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$9.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.3% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.Select Competitors (Total 27 Featured) -
  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
ADHD Therapeutics: A Primer
Recent Market Activity
ADHD Therapeutics Market Outlook
Factors Driving ADHD Therapeutics Market
Changes in Insurance Coverage
Addition of Formal Guidelines
Low Diagnosis Threshold
Advancements in Field of Medicine
Unmet Needs
Launch of Pipeline Drugs
Factors Inhibiting ADHD Therapeutics Market
Side Effects Related to Use of Stimulants to Treat ADHD
Under-diagnosis of ADHD Condition
Reduced Availability of Non-Stimulants in Certain Geographies
Competitive Landscape
Major ADHD Medications Available in the Market
ADHD Medications Approved by FDA
Patent Validity for Major ADHD Drugs
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
Alcobra Ltd. (Israel)
Amarantus Bioscience Holdings, Inc. (US)
Amedra Pharmaceuticals LLC (US)
Curemark, LLC. (US)
Eli Lilly and Company (US)
Intellipharmaceutics International, Inc. (US)
Janssen Global Services, LLC (US)
Mallinckrodt PLC (Ireland)
Mylan N.V. (The Netherlands)
Neos Therapeutics, Inc. (US)
Neurovance, Inc. (US)
Noven Pharmaceuticals, Inc. (US)
Pfizer Inc. (US)
Shire plc (Ireland)
Supernus Pharmaceuticals, Inc. (US)
Tris Pharma, Inc. (US)
3. MARKET TRENDS & DRIVERS
Biological Psychiatry Gaining Ground
Social Media Drives Heightened Awareness
Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity
Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market
Strategic Alliances
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Non-Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 22: World Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
JAPAN
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 47: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
CHINA
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 50: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 53: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 56: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
EUROPE
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 59: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 65: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
FRANCE
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 71: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 74: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 77: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
GERMANY
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 80: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 83: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 86: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
ITALY
TABLE 89: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 92: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 95: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
UNITED KINGDOM
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 98: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 101: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 104: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 125: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
TABLE 128: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
TABLE 131: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings